RLIP76在肿瘤靶向治疗的研究进展

Research Progress of RLIP76 in Targeted Therapy of Tumor

过去20年里,全球癌症发病率处于快速上升阶段,癌症的治疗一直是医学界的难题。目前常规化疗药物的主要缺点是选择性较低,对肿瘤的治疗效果较差。具有高度特异性的靶向治疗对患者的治疗效果更好,不良反应更少。靶向治疗的开发具有良好的前景。RLIP76是一种多药转运体和抗凋亡蛋白,是化疗耐药和癌细胞信号转导的关键分子之一。RLIP76在癌细胞中存在固有的过度表达,而正常细胞对RLIP76的依赖性相对较小,这为认识RLIP76作为一种独特的抗癌靶点的潜力提供了证据。在许多癌细胞系和异种移植物中,通过抑制RLIP76触发凋亡通路,一致观察到的退化结果为RLIP76在临床上作为一种新的治疗药物提供了一定的思路。

In the past 20 years,the global incidence of cancer has been rising rapidly and the treatment of cancer has always been a challenge for the medical community.At present,the main shortcomings of conventional chemotherapy drugs are low selectivity and poor therapeutic effect on tumors.Targeted therapy with high specificity has a better therapeutic effect on patients with fewer ad-verse reactions.The development of targeted therapy has a good prospect.RLIP76 is a multidrug transporter and anti-apoptotic protein,which is one of the key molecules in chemotherapy re-sistance and signal transduction of cancer cells.RLIP76 is inherently overexpressed in cancer cells,while normal cells have relatively little dependence on RLIP76,which provides evidence for ac-knowledging RLIP76’s potential as a unique anticancer target.In many cancer cell lines and xeno-grafts,by inhibiting RLIP76 to trigger the apoptotic pathway,the consistently observed degradation results provide some ideas for RLIP76 as a new therapeutic drug in clinical practice.